The Evaluation of Psychopharmacological Enhancers Beyond a Normative “Natural”–“Artificial” Dichotomy
Tóm tắt
The extra-therapeutic use of psychotropic drugs to improve cognition and to enhance mood has been the subject of controversial discussion in bioethics, in medicine but also in public for many years. Concerns over a liberal dealing with pharmacological enhancers are raised not only from a biomedical–pharmacological perspective, but particularly from an ethical one. Within these ethical concerns, there is one objection about the normative differentiation between “natural” and “artificial” enhancers, which is theoretically indeed widely discredited in bioethics, which has, however, entrenched itself in such a persistent way in everyday moral consciousness that it keeps a crucial influence on the assessment of pharmacological enhancers made by the public and medical professionals. This paper tries to first show why a normative differentiation between “natural” and “artificial” enhancers is highly problematic. In a second step, the resulting implications for our current dealing with pharmacological enhancers shall be examined. In a specific comparison of synthetic pharmaceuticals (modafinil, SSRIs) with phytopharmaceuticals (ginkgo biloba, St. John’s wort) and other already established enhancers (alcohol, caffeine), argumentative inconsistencies are pointed out which, at least partly, result from a rationally untenable preference for the “natural” over the “artificial”. Therefore, it is conclusively argued the case for an unprejudiced assessment of pharmacological enhancers beyond a “natural”–“artificial” dichotomy, which equally takes into account biomedical and ethical aspects. The goal is to reach a coherent dealing with pharmacological enhancement in the long run.
Tài liệu tham khảo
Ach, J.S., and A. Pollmann, eds. 2006. No body is perfect. Baumaßnahmen am menschlichen Körper; bioethische und ästhetische Aufrisse. Bielefeld: transcript.
Bayertz, K. 2003. Human nature: How normative might it be? Journal of Medicine and Philosophy 28(2): 131–150.
Beddington, J., et al. 2008. The mental wealth of nations. Nature 455: 1057–1060.
Benkert, O., and H. Hippius, eds. 2011. Kompendium der Psychiatrischen Pharmakotherapie. Berlin: Springer Medizin Verlag.
Berger, M. et al. 2009. Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Nervenheilkunde (DGPPN) zum Gebrauch von Neuroenhancern. http://www.dgppn.de/fileadmin/user_upload/_medien/download/pdf/stellungnahmen/2009/stn2009-11-24-neuroenhancer.pdf. Accessed 3 December 2010.
Birks, J., and E.J. Grimley. 2009. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database of Systematic Reviews 1: Art. No.: CD003120.
Birnbacher, D. 2006a. “Natur” als Maßstab menschlichen Handelns. In Bioethik zwischen Natur und Interesse, ed. D. Birnbacher, 145–165. Frankfurt am Main: Suhrkamp.
Birnbacher, D. 2006b. Natürlichkeit. Berlin: de Gruyter.
Bogle, K.E., and B.H. Smith. 2009. Illicit methylphenidate use: A review of prevalence, availability, pharmacology, and consequences. Current drug abuse reviews 2(2): 157–176.
British Medical Association. 2007. Boosting your brainpower: Ethical aspects of cognitive enhancements. A discussion paper from the British Medical Association. http://www.bma.org.uk/images/Boosting_brainpower_tcm41-147266.pdf. Accessed 3 Dec 2010.
Charlton, B.G. 2003. Palliative psychopharmacology: A putative speciality to optimize the subjective quality of life. QJM: Monthly Journal of the Association of Physicians 96: 375–378.
Charlton, B.G. 2001. The potential for pharmacological treatment of unpleasant psychological symptoms to increase personal fulfillment in old age. QJM: Monthly Journal of the Association of Physicians 94(6): 333–336.
Chatterjee, A. 2004. Cosmetic neurology: The controversy over enhancing movement, mentation, and mood. Neurology 63(6): 968–974.
Clayton, A.H., and A.L. Montejo. 2006. Major depressive disorder, antidepressants, and sexual dysfunction. The Journal of clinical psychiatry 67(Suppl. 6): 33–37.
Craik, F.I.M., and T.A. Salthouse, eds. 2008. The handbook of aging and cognition. New York: Psychology Press.
Dees, R.H. 2008. Better brains, better selves? The ethics of neuroenhancements. Kennedy Institute of Ethics Journal 17(4): 371–395.
Dees, R.H. 2004. Slippery slopes, wonder drugs, and cosmetic neurology: The neuroethics of enhancement. Neurology 63(6): 951–952.
Degrazia, D. 2000. Prozac, enhancement, and self-creation. The Hastings Center report 30(2): 34–40.
de Jongh, R., et al. 2008. Botox for the brain: Enhancement of cognition, mood and pro-social behavior and blunting of unwanted memories. Neuroscience and Biobehavioral Reviews 32(4): 760–776.
Dekant, W. 2005. Alkohole. In Allgemeine und spezielle Pharmakologie und Toxikologie, ed. K. Aktories, et al., 1041–1049. München: Elsevier Urban & Fischer.
Farah, M.J. 2002. Emerging ethical issues in neuroscience. Nature Neuroscience 5: 1123–1129.
Farah, M.J., et al. 2004. Neurocognitive enhancement: What can we do and what should we do? Nature Reviews Neuroscience 5(5): 421–425.
Ferré, S. 2008. An update on the mechanisms of the psychostimulant effects of caffeine. Journal of Neurochemistry 105: 1067–1079.
Filipp, S.-H., and A.-K. Mayer. 2005. Zur Bedeutung von Altersstereotypen. Aus Politik und Zeitgeschichte 49(50): 25–31.
Fink, H., and R. Rosenzweig, eds. 2010. Künstliche Sinne, gedoptes Gehirn. Neurotechnik und Neuroethik. Paderborn: Mentis.
Förstl, H. 2009. Neuro-Enhancement. Gehirndoping. Der Nervenarzt 80(7): 840–846.
Franke, A.G., and K. Lieb. 2009. Missbrauch von Psychopharmaka zum “cognitive enhancement”. Mit Hirndoping zu intellektuellen Spitzenleistungen? INFO Neurologie & Psychiatrie 11(7–8): 42–50.
Galert, T., et al. 2009. Das optimierte Gehirn. Gehirn & Geist 11: 40–48.
Gather, J. (in preparation). Glück für die alternde Gesellschaft!? Zur Anwendbarkeit und sozialen Wünschbarkeit psychopharmakologischen Enhancements im demographischen Wandel.
Gesang, B. 2007. Perfektionierung des Menschen. Berlin: de Gruyter.
Gesang, B. 2006. “Enhancement” zwischen Selbstbetrug und Selbstverwirklichung. Ethik in der Medizin 18: 10–26.
Glannon, W. 2008. Psychopharmacological enhancement. Neuroethics 1: 45–54.
Glannon, W., ed. 2007a. Bioethics and the brain. Oxford: Oxford University Press.
Glannon, W., ed. 2007b. Defining right and wrong in brain science. Essential readings in neuroethics. New York: Dana Press.
Greely, H., et al. 2008. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 456: 702–705.
Groß, D. 2009. Blessing or Curse? Neurocognitive enhancement by “brain engineering”. Medicine Studies 1: 379–391.
Higdon, J.V., and B. Frei. 2006. Coffee and health: A review of recent human research. Critical Reviews in Food Science and Nutrition 46: 101–123.
Hofer, S.M., and D.F. Alwin, eds. 2008. Handbook of cognitive aging. Interdisciplinary perspectives. Los Angeles: Sage.
Huber, L., and L.K. Kutschenko. 2009. Medicine in a neurocentric world: About the explanatory power of neuroscientific models in medical research and practice. Medicine Studies 1: 307–313.
Juliano, L.M., and R.R. Griffiths. 2004. A critical review of caffeine withdrawal: Empirical validation of symptoms and signs, incidence, severity, and associated features. Psychopharmacology 176: 1–29.
Kampf, A., and L.A. Botelho. 2009. Anti-aging and biomedicine: Critical studies on the pursuit of maintaining, revitalizing and enhancing aging bodies. Medicine Studies 1: 187–195.
Katz, S., and K.R. Peters. 2008. Enhancing the mind? Memory medicine, dementia, and the aging brain. Journal of Aging Studies 22: 348–355.
Killgore, W.D., et al. 2009. Sustaining executive functions during sleep deprivation: A comparison of caffeine, dextroamphetamine, and modafinil. Sleep 32(2): 205–216.
Klinkhammer, G. 2009. Auf dem Weg zum optimierten Gehirn. Deutsches Ärzteblatt 106(44): A2179.
Kocka, J. 2008. Chancen und Herausforderungen einer alternden Gesellschaft. In Was ist Alter(n)? Neue Antworten auf eine scheinbar einfache Frage, eds. U.M. Staudinger, and H. Häfner, 217–236. Berlin: Springer.
Kramer, P. 1997. Listening to prozac. New York: Penguin Books.
Kruse, A., and H.-W. Wahl, eds. 2010. Zukunft Altern. Individuelle und gesellschaftliche Weichenstellungen. Heidelberg: Spektrum Akad.-Verlag.
Lehr, U. 2007. Psychologie des Alterns. Wiebelsheim: Quelle & Meyer.
Levy, N. 2007. Neuroethics. Challenges for the 21st century. Cambridge: Cambridge University Press.
Lieb, K. 2010. Hirndoping. Warum wir nicht alles schlucken sollten. Mannheim: Artemis & Winkler.
Linde, K. et al. 2008. St John′s wort for major depression. Cochrane Database of Systematic Reviews 4: Art. No.: CD000448.
Maher, B. 2008. Poll results: Look who′s doping. Nature 452: 674–675.
McCabe, S.E., et al. 2005. Non-medical use of prescription stimulants among US college students: Prevalence and correlates from a national survey. Addiction 100(1): 96–106.
Merkel, R. et al., ed. 2007. Intervening in the brain. Changing psyche and society. Berlin: Springer.
Metzinger, T. 2009. Der Ego-Tunnel. Eine neue Philosophie des Selbst: Von der Hirnforschung zur Bewusstseinsethik. Berlin: Berlin-Verlag.
Minzenberg, M.J., and C.S. Carter. 2008. Modafinil: A review of neurochemical actions and effects on cognition. Neuropsychopharmacology 33: 1477–1502.
Müller, W.E. 2003. Current St. John′s wort research from mode of action to clinical efficacy. Pharmacological Research 47: 101–109.
Normann, C., and M. Berger. 2008. Neuroenhancement: Status quo and perspectives. European Archives of Psychiatry and Clinical Neuroscience 258(Suppl. 5): 110–114.
Parens, E., ed. 1998. Enhancing human traits. Ethical and social implications. Washington, DC: Georgetown University Press.
President’s Council on Bioethics (PCB), ed. 2003. Beyond Therapy: Biotechnology and the Pursuit of Happiness. A report of The President’s Council on Bioethics. Washington, DC: US Government Printing Office. http://biotech.law.lsu.edu/research/pbc/reports/beyondtherapy/beyond_therapy_final_report_pcbe.pdf . Accessed 3 Dec 2010.
Repantis, D., et al. 2009. Antidepressants for neuroenhancement in healthy individuals: A systematic review. Poiesis & Praxis 6: 139–174.
Rose, S. 2006. The future of the brain. The promise and perils of tomorrow’s neuroscience. Oxford: Oxford University Press.
Roughley, N. 2005. Was heißt “menschliche Natur”? Begriffliche Differenzierungen und normative Ansatzpunkte. In Die menschliche Natur. Welchen und wieviel Wert hat sie?, ed. K. Bayertz, 133–156. Paderborn: Mentis.
Sahakian, B., and S. Morein-Zamir. 2007. Professor′s little helper. Nature 450: 1157–1159.
Savulescu, J., and N. Bostrom, eds. 2009. Human enhancement. Oxford: Oxford University Press.
Schäfer, G., and D. Groß. 2008. Eingriff in die personale Identität. Die Argumente für psychopharmakologisches Enhancement greifen zu kurz. Deutsches Ärzteblatt 105(5): A210–A212.
Schermer, M. 2008. On the argument that enhancement is “cheating”. Journal of Medical Ethics 34: 85–88.
Schmidt, L.G. 2005. Begriffsbestimmungen. In Alkohol und Alkoholfolgekrankheiten. Grundlagen—Diagnostik—Therapie, eds. M.V. Singer and S. Teyssen, 29–34. Berlin: Springer Medizin Verlag.
Schöne-Seifert, B. et al., ed. 2009. Neuro-Enhancement. Ethik vor neuen Herausforderungen. Paderborn: Mentis.
Schöne-Seifert, B., and D. Talbot, eds. 2009. Enhancement. Die ethische Debatte. Paderborn: Mentis.
Solomon, P., et al. 2002. Ginkgo for Memory Enhancement. A Randomized Controlled Trial. JAMA 288: 835–840.
Starke, K. 2005. Methylxanthine. In Allgemeine und spezielle Pharmakologie und Toxikologie, ed. K. Aktories, et al., 187–191. München: Elsevier Urban & Fischer.
Stork, S.W. 2007. Neuropharmaceuticals: A historical perspective. In Sind die Gedanken frei? Die Neurowissenschaften in Geschichte und Gegenwart, eds. D. Groß and S. Müller, 208–225. Berlin: Medizinisch Wissenschaftliche Verlagsgesellschaft.
Szentpetery, V. July 2008. Die gedopte Elite. Technology Review: 34–39.
Vincent, J.A. 2008. The cultural construction old age as a biological phenomenon: Science and anti-ageing technologies. Journal of Aging Studies 22: 331–339.
Wesensten, N.J., et al. 2005. Performance and alterness effects of caffeine, dextroamphetamine, and modafinil during sleep deprivation. Journal of Sleep Research 14: 255–266.
Zhou, S., et al. 2004. Pharmakokinetic interactions of drugs with St John’s wort. Journal of Psychopharmacology 18(2): 262–276.